Evolent Clinical Guideline 3198 for Sarclisa™ (isatuximab-irfc)

Guideline Number:	Applicable Codes	
Evolent_CG_3198		
"Evolent" refers to Evolent Health LLC and Evolent Specialty Services, Inc.		
Original Date:	**Last Revised Date:**	**Implementation Date:**
April 2020	October 2025	October 2025

TABLE OF CONTENTS

STATEMENT

Purpose

To define and describe the accepted indications for Sarclisa (isatuximab-irfc) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Multiple Myeloma (MM)

- Sarclisa (isatuximab-irfc) may be used in combination with Velcade (bortezomib), Revlimid (lenalidomide) and steroid, for the treatment of adult members with newly diagnosed multiple myeloma, regardless if they areeligible or not for autologous stem cell transplant (ASCT).
- Sarclisa (isatuximab-irfc) may be used for adult members with relapsed or refractory MM who have not received any prior therapy with Darzalex (daratumumab) and ANY of the following:
    - Sarclisa (isatuximab-irfc) is being used in combination with Pomalyst (pomalidomide) and steroid AND the member has failed 2 prior therapies with a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib), and an immunomodulatory agent (e.g., lenalidomide, thalidomide) other than Pomalyst (pomalidomide) OR
    - Sarclisa (isatuximab-irfc) is being used in combination with Kyprolis (carfilzomib) and steroid following 1 prior line of therapy that did not include Kyprolis (carfilzomib).

CONTRAINDICATIONS/WARNINGS

- Contraindications
  - Severe hypersensitivity to isatuximab or any component of the formulation.

EXCLUSION CRITERIA

- Sarclisa (isatuximab-irfc) is being used on or after disease progression with the same regimen or after disease progression on a daratumumab-based regimen.
- Dosing exceeds single dose limit of Sarclisa (isatuximab-irfc) 10 mg/kg.
- Investigational use of Sarclisa (isatuximab-irfc) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J9227 - Injection, isatuximab-irfc, 10 mg

Applicable Lines of Business

☐	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☐	Medicare Advantage

POLICY HISTORY

Date	Summary
October 2025	• Converted to new Evolent guideline template • This guideline replaces UM ONC_1393 Sarclisa (isatuximab-irfc) • Updated indication section to include use for transplant-eligible NDMM in combination with VRd • Updated references
October 2024	• Updated indication section to include use for transplant-ineligible NDMM in combination with VRd • Updated references

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure

codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Mai EK, et al; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. *J Clin Oncol*. 2025 Apr 10;43(11):1279-1288. doi: 10.1200/JCO-24-02266.
2. Attal M, et al; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5.
3. Facon T, et al; IMROZ Study Group. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712.
4. Moreau P, et al; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4.
5. Sarclisa prescribing information. sanofi-aventis U.S. LLC. Morristown, NJ 2025.
6. Clinical Pharmacology Elsevier Gold Standard 2025.
7. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
8. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
9. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
10. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
11. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: **https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf**.
12. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: **http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm**.